Combs Andrew 4
4 · Prelude Therapeutics Inc · Filed Feb 5, 2025
Insider Transaction Report
Form 4
Combs Andrew
Chief Chemistry Officer
Transactions
- Award
Employee Stock Option (right to buy)
2025-02-04+175,000→ 175,000 totalExercise: $1.11Exp: 2035-02-04→ Common Stock (175,000 underlying)
Footnotes (1)
- [F1]The stock option vests as to 25% of the total shares on Feb 4, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.